小智港股覆盤 | 1月19日
今日，港股三大指數漲跌互現。截止收盤，恆生指數漲0.06%，報24127點。國企指數跌0.09%，報8441點。恆生科技指數跌0.98%，報5642點。市場約832只個股上漲，838只個股下跌。成交額突破1149.62億港幣，和昨天同期相比增長2.36%。南下資金淨流入5.91億港幣。
盤面上，建築建材板塊全線走強。佳辰控股漲超13%；遠大中國、中國聯塑等多股漲超8%；中國玻璃漲超5%；美亨實業漲超1%。遠大中國，獲Neo Pioneer Limited增持324.6萬股；花旗下調中國聯塑目標價至18.8元，評級「買入」。
商業服務板塊暴漲。REF HOLDINGS漲超12%；旭輝永升服務、新城悅服務等多股漲超10%；碧桂園服務、環球印館等多股漲超8%。匯豐研究上調中海外目標價至29元，降碧桂園及碧桂園服務目標價。
建築材料板塊漲幅較前。同方康泰漲超6%；中國建材漲超5%；海螺水泥、華潤水泥控股等多股漲超4%；中國天瑞水泥漲超3%。中國建材擬發行不超過20億元公司債；中金：維持華潤水泥控股“跑贏行業”評級，目標價9.98港元。
汽車板塊跌幅居前。小鵬汽車-W跌超5%；理想汽車-W跌超4%；科軒動力控股、比亞迪股份等多股跌超3%；東風集團股份跌超2%。麥格理首予小鵬汽車-W「跑贏大市」評級，目標價221元；麥格理首予理想汽車-W「跑贏大市」評級，目標價151元；比亞迪股份“19亞迪01”票面利率擬調整至2.50%。
CRO板塊跌幅居前。奧星生命科技跌超68%；藥明康德跌超7%；昭衍新藥、維亞生物、康龍化成等多股跌超3%。建銀國際：維持藥明康德“優於大市”評級，目標價降8.72%至178港元；UBS Group AG增持昭衍新藥10.58萬股，每股作價約62.72港元；小摩增持維亞生物132.75萬股，每股作價約4.52港元；康龍化成：限制性股票回購註銷完成，註冊資本減至7.94億元。
航天國防板塊跌幅較前。中航科工跌超3%；光啓科學跌超2%。中航科工：中航光電非公開發行A股股票完成，公司參與認購209.27萬股。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
